Safety and Acceptability of Three Ablation Treatments for High-Grade Cervical Precancer: Early Data From a Randomized Noninferiority Clinical Trial.
Journal
JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
21
12
2022
Statut:
ppublish
Résumé
This ongoing trial is comparing the efficacy and safety of three ablation treatments for cervical intraepithelial neoplasia grade 2 or higher. Here, we present early data regarding pain, side effects, and acceptability of CO This noninferiority randomized trial is taking place in El Salvador, China, and Colombia. Patients are 1,152 eligible women with biopsy-confirmed cervical intraepithelial neoplasia grade 2 or higher who will receive one of three ablation treatments. Pain is measured before, during, and after treatment with a visual analog scale (1-10). Side effects and acceptability are assessed at 6 weeks. To date, 1,024 of 1,152 (89%) women were randomly assigned to treatment. The median pain level was higher during TA (4, IQR = 4) than CO Despite differences in pain and side effects across ablation treatments, all were safe and highly acceptable to patients. In addition to efficacy, considerations such as cost and portability may be more significant in choosing a treatment method.
Identifiants
pubmed: 36525620
doi: 10.1200/GO.22.00112
pmc: PMC10166394
doi:
Substances chimiques
Carbon Dioxide
142M471B3J
Banques de données
ClinicalTrials.gov
['NCT03084081']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2200112Subventions
Organisme : NCI NIH HHS
ID : UH3 CA189883
Pays : United States
Références
Okla Nurse. 1988 Mar;33(1):8
pubmed: 3368206
Int J Gynecol Cancer. 2019 May 3;:
pubmed: 31055452
Int J Gynaecol Obstet. 2008 Dec;103(3):232-6
pubmed: 18817909
Int J Womens Health. 2017 Dec 01;9:879-886
pubmed: 29238232
Trop Med Int Health. 2019 Dec;24(12):1391-1399
pubmed: 31622526
Prev Med. 2019 Jan;118:81-91
pubmed: 30342109
J Midwifery Womens Health. 2005 Jul-Aug;50(4):335-40
pubmed: 15973272
Br J Cancer. 2007 Mar 12;96(5):738-43
pubmed: 17311015
BJOG. 2014 Jul;121(8):929-42
pubmed: 24597779
JCO Glob Oncol. 2020 Jul;6:1024-1033
pubmed: 32634066
Int J Gynaecol Obstet. 2015 Apr;129(1):62-6
pubmed: 25593107
J Low Genit Tract Dis. 2018 Jan;22(1):47-51
pubmed: 29271857
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Int J Gynaecol Obstet. 2016 Mar;132(3):266-71
pubmed: 26643302
Int J Gynaecol Obstet. 2011 Sep;114(3):268-72
pubmed: 21752376
Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:63-68
pubmed: 28691331
Int J Gynaecol Obstet. 2013 Mar;120(3):218-23
pubmed: 23265830
BMJ Open. 2018 Jun 12;8(6):e020484
pubmed: 29895648
Cochrane Database Syst Rev. 2013 Dec 04;(12):CD001318
pubmed: 24302546
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncologist. 2013;18 Suppl:6-12
pubmed: 24334477
Int J Cancer. 2021 Jul 15;149(2):371-377
pubmed: 33687746
Lancet Oncol. 2020 Jan;21(1):175-184
pubmed: 31734069
Lancet Oncol. 2020 Jan;21(1):19-20
pubmed: 31734070
BMC Womens Health. 2017 Jan 7;17(1):2
pubmed: 28061842
Int J Gynaecol Obstet. 2017 Jul;138 Suppl 1:20-25
pubmed: 28691333
Int J Gynaecol Obstet. 2016 Jun;133(3):351-4
pubmed: 27005927
J Obstet Gynaecol Res. 2021 Jan;47(1):279-286
pubmed: 33089619
BMC Womens Health. 2016 May 11;16:25
pubmed: 27169666
Int J Cancer. 2020 Sep 1;147(5):1275-1285
pubmed: 31970767
Oncol Lett. 2020 Sep;20(3):2058-2074
pubmed: 32782524
IEEE J Transl Eng Health Med. 2017 Nov 23;5:2800514
pubmed: 29204328
Glob Health Sci Pract. 2017 Mar 28;5(1):57-64
pubmed: 28351879
Int J Gynaecol Obstet. 2012 Aug;118(2):97-102
pubmed: 22727415
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
BMJ Open. 2021 Sep 14;11(9):e049901
pubmed: 34521669
Int J Cancer. 2016 Aug 15;139(4):908-15
pubmed: 27006131